Details

Autor(en) / Beteiligte

• Gallardo-Rincón, Héctor
• Montoya, Alejandra
• Saucedo-Martínez, Rodrigo
• Mújica-Rosales, Ricardo
• Suárez-Idueta, Lorena
• Martínez-Juárez, Luis Alberto
• Razo, Christian
• Lozano, Rafael
• Tapia-Conyer, Roberto

Titel

Integrated Measurement for Early Detection (MIDO) as a digital strategy for timely assessment of non-communicable disease profiles and factors associated with unawareness and control: a retrospective observational study in primary healthcare facilities in Mexico

Ist Teil von

• BMJ open, 2021-09, Vol.11 (9), p.e049836-e049836

Ort / Verlag

London: BMJ Publishing Group LTD

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• ObjectivesThe Carlos Slim Foundation implemented the Integrated Measurement for Early Detection (MIDO), a screening strategy for non-communicable diseases (NCDs) in Mexico as part of CASALUD, a portfolio of digital health services focusing on healthcare delivery and prevention/management of NCDs. We investigated the disease profile of the screened population and evaluated MIDO’s contribution to the continuum of care of the main NCDs.DesignUsing data from MIDO and the chronic diseases information system, we quantified the proportion of the population screened and diagnosed with NCDs, and measured care linkage/retention and level of control achieved. We analysed comorbidity patterns and estimated prevalence of predisease stages. Finally, we estimated characteristics associated with unawareness and control of NCDs, and examined efficacy of the CASALUD model in improving NCD control.SettingPublic primary health centres in 27/32 Mexican states.ParticipantsIndividuals aged ≥20 years lacking healthcare access.ResultsFrom 2014 to 2018, 743 000 individuals were screened using MIDO. A predisease or disease condition was detected in ≥70% of the population who were unaware of their NCD status. The screening identified 38 417 new cases of type 2 diabetes, 53 133 new cases of hypertension and 208 627 individuals with obesity. Dyslipidaemia was found in 77.3% of individuals with available blood samples. Comorbidities were highly prevalent, especially in people with obesity. Only 5.47% (n=17 774) of individuals were linked with their corresponding primary health centre. Factors associated with unawareness of and uncontrolled NCDs were sex, age, and social determinants, for example, rural/urban environment, access to healthcare service, and education level. Patients with type 2 diabetes treated at clinics under the CASALUD model were more likely to achieve disease control (OR: 1.32, 95% CI: 1.09 to 1.61).ConclusionPatient-centred screening strategies such as MIDO are urgently needed to improve screening, access, retention and control for patients with NCDs.